Publications
Publications
Show Results For
- All HBS Web
(506)
- Faculty Publications (354)
- May 2015
- Case
Acıbadem Healthcare Group
By: Regina E. Herzlinger, Esel Çekin, Natalie Kindred and Gamze Yucaoglu
Acıbadem Healthcare Group is Turkey's only premium nationwide hospital network. This case focuses on Acıbadem’s potential expansion strategy after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest publicly listed... View Details
- May 2015
- Supplement
OdontoPrev (B)
- March 2015 (Revised November 2017)
- Case
Bonitas
By: Regina E. Herzlinger and Natalie Kindred
Bonitas, a South African medical scheme (i.e., health insurer), must navigate highly restrictive regulations that make it difficult for Bonitas to innovate, grow, and compete with market leader Discovery as well as providers of alternative insurance products. Bonitas... View Details
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- 2015
- Other Teaching and Training Material
Innovating in Healthcare
By: Regina E. Herzlinger, Margo I. Seltzer and Kevin Schulman
With over 71,000 past enrollees, Innovating in Healthcare investigates the issues of health care spending, quality, and access that continue to plague America and global nations alike. With U.S. health care costs trending toward $4 trillion in 2020, the need to... View Details
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details
- September 2014 (Revised March 2021)
- Case
La Ribera Health Department (A)
By: Regina E. Herzlinger, Emer Moloney and Daniela Beyersdorfer
The La Ribera case studies depict an innovative low cost/high quality privately financed hospital model struggling to achieve alignment with the Six Factors. It is reimbursed by the public sector in a Spanish environment whose Consumers, Structure, and Public Policy... View Details
- August 2014
- Case
Blue Cross Blue Shield of Florida, Inc.
By: Regina E. Herzlinger and Meng Li
- August 2014 (Revised February 2021)
- Case
Hospital for Special Surgery (A)
By: Regina E. Herzlinger and Stacy Schwartz
Hospital for Special Surgery, a focused factory for orthopedics and joint disease, is contemplating various growth options: further growth in the United Kingdom's National Health Services, management of hospitals in the United States, and/or hospital consulting.... View Details
- Article
Shifting toward Defined Contributions—Predicting the Effects
By: Kevin Schulman, Barak D. Richman and Regina E. Herzlinger
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details
Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States
- Blog Post
Health Care Transparency: The Fox Is Guarding the Chicken Coop in Washington Again
Now that more people can shop directly for their own health insurance under the Affordable Care Act, they have been transformed from potential patients to consumers, and like any other consumers of goods or services, they want to know if what they're buying is any... View Details
- March 2014 (Revised September 2014)
- Supplement
Cancer Treatment Centers of America® (B)
By: Regina E. Herzlinger and Natalie Kindred
This case, a follow-up to Cancer Treatment Centers of America (A), HBS No. 313-012, begins with the debate over New Hampshire's certificate-of-need (CON) law, which restricts hospital expansion. This debate ignited significant public criticism of Cancer Treatment... View Details
Keywords: Cancer; Cancer Treatment; Accountability; Outcomes; Outcomes Reporting; Outcomes Measurement; Survival; For-profit Hospitals; Health Care; Healthcare; Hospital; Certificate Of Need; Health Care and Treatment; Outcome or Result; Corporate Accountability; Policy; Health Industry; United States
- December 2013 (Revised February 2014)
- Supplement
Reinventing Brainlab (B)
By: Regina E. Herzlinger and Karol Misztal
The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details
- January–February 2014
- Other Article
Barriers to Health Care Innovation: Regina Herzlinger Warns That Innovators Need to Know What Obstacles They Face and How to Overcome Them
Health care in the United States and in most other developed countries is ailing, says Regina E. Herzlinger. A chaired professor of business administration specializing in health care at Harvard Business School, Herzlinger says that although the world has witnessed... View Details
- November 2013
- Teaching Note
Vitalia Franchise
Keywords: Entrepreneurship; Health Care and Treatment; Ownership; Expansion; Health; Health Industry; Spain
- September 2013 (Revised August 2014)
- Case
Ping An Health (PAH): Towards a Comprehensive Private Health Insurance Market in China
By: Regina E. Herzlinger and Da Liu
- August 2013 (Revised August 2014)
- Technical Note
Health Information Exchanges
By: Regina E. Herzlinger and Kyle Bertke
Companion background note to AxSys. View Details
- August 2013 (Revised August 2014)
- Technical Note
Population Health Management—Techniques and Tools
By: Regina E. Herzlinger and Kyle Bertke
Companion note to "Amil and the Health Care System in Brazil," Harvard Business School Case No. 312-029, January 2014 View Details